Search
for
Sort by
Research 211–240 of 1000+
- Alopecia areata
- A retrospective analysis of disease epidemiology, comorbidities, treatment patterns, and healthcare resource utilization of alopecia areata in the United Arab Emirates using claims database
- Comparative efficacy and safety of systemic steroids, oral JAK inhibitors and Contact Immunotherapy in the Treatment of severe alopecia areata: a systematic review and network meta-analysis
- COMPARISON OF EFFICACY OF BARICITINIB VERSUS METHOTREXATE THERAPY IN THE TREATMENT OF SEVERE ALOPECIA AREATA
- Systemic Treatment of Moderate to Severe Alopecia Areata in Adults: Updated Australian Expert Consensus Statement
- A systematic review of tumor necrosis factor-α blockers, anti-interleukins, and small molecule inhibitors for dissecting cellulitis of the scalp treatment
- Dermatological Indications: Alopecia Areata
- Effects of oxytocin receptor agonists on hair growth promotion
- Successful treatment of alopecia areata‐associated trachyonychia with baricitinib
- Treatments for alopecia areata: a network meta-analysis
- Human Leukocyte Antigen Class II Alleles Are Associated with Risk of Alopecia Areata
- Dermatologist and Patient Perceptions of Treatment Success in Alopecia Areata and Evaluation of Clinical Outcome Assessments in Japan
- Eyebrow and Eyelash Alopecia: A Clinical Review
- An Evaluation of Generic and Disease‐Specific Patient‐Reported Outcome Measures to Assess the Impact of Percentage of Scalp Hair Loss on Health‐Related Quality of Life in a European Population
- T <sub>H</sub> 1 effector CD4 T cells rely on IFN-γ production to induce alopecia areata
- Brave New World
- Baricitinib Achieved Complete/Near Complete Scalp Coverage in SALT Score ≤20 Responders: 52-Week Findings From BRAVE-AA Trials
- Nail Brace Application
- Outcomes of Down-Titration in Patients With Severe Scalp Alopecia Areata Treated With Baricitinib: An Update Through Week 152 From BRAVE-AA2
- Folliculin: A surprising molecular brake in the human hair follicle
- 43046 Outcomes of Down-Titration in Patients with Severe Scalp Alopecia Areata Treated with Baricitinib 4 Mg: Week 104 Data from BRAVE-AA2
- Eyebrows and Eyelashes Regrowth Across Different SALT Response Thresholds in Patients with Alopecia Areata: Outcomes from the BRAVE AA Clinical Program
- Herpes Zoster y COVID 19, coexistencia en un paciente no inmunodeprimido. Reporte de un caso y breve revisión a propósito del mismo.
- Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib
- Fifty-six years of plastic surgery
- Foxn1 promotes keratinocyte differentiation by regulating the activity of protein kinase C
- Wear characteristics of epoxy based hybrid composites reinforced with short hair fibers and glass micro spheres
- Effectiveness of Baricitinib for Nasal, Genital, and Beard Hair Regrowth in Patients with Severe Alopecia Areata: 12-Month Outcomes from a Prospective Observational Study
- Baricitinib regrows hair in adolescents with alopecia areata
- Olumiant® (Baricitinib)-A Newly Approved Janus Kinase Inhibitor for the Treatment of Alopecia Areata.